US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
Yesterday 19:59
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk Oct 26 (Reuters) - A U.S. court on Monday allowed Eli Lilly LLY.N to continue weight-loss drug advertisements that rival Novo Nordisk NOVOb.CO claimed were false and misleading.
(Reporting by Jonathan Stempel in New York)
(((( jon.stempel@thomsonreuters.com ; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net /))))
Recent news on Eli Lilly and
See all newsHengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals
Indian drugmaker Cipla misses profit view on US weakness, shares slip (updated)
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk (updated)
Corrected: UPDATE 2-US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk